The final hours and days are ticking away on a $6B bet as deadline looms on a suspenseful FDA decision
The clock is ticking down to the year-end deadline for an FDA approval of liso-cel, and the suspense is killing investors.
You’ll recall that Bristol Myers CEO Giovanni Caforio insisted at the last minute of negotiations with Celgene execs that they had to replace cash on the table with a CVR $BMYRT tied to 3 key drug approvals by a certain deadline.
That’s all 3. Miss one, and anyone holding on to the $9 CVR would get nothing. For Bristol Myers, it’s a $6 billion play.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.